Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009


News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

React to this article
Latest news on CYTOKINETICS, INC.
02/27 CYTOKINETICS : Joins Global Movement to Raise Awareness for Rare Diseases
02/26 ASTELLAS PHARMA : Cytokinetics Announces Publication of Preclinical Data Relatin..
02/24 CYTOKINETICS : to Announce Fourth Quarter Results on February 12, 2015
02/24 CYTOKINETICS : to Present at Healthcare Conferences in March
02/13 CYTOKINETICS : Reports Fourth Quarter 2014 Financial Results
02/12 CYTOKINETICS : posts 4Q profit
02/12 CYTOKINETICS : Announces Additional Results from BENEFIT-ALS
02/12 CYTOKINETICS : Results of Operations and Financial Condition, Financial Statemen..
02/12 CYTOKINETICS : Incorporated Reports Fourth Quarter 2014 Financial Results
02/10 CYTOKINETICS : Change in Directors or Principal Officers (form 8-K)
Income Statement Evolution
More Financials
Dynamic quotes